Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

ClinicalTrials.gov ID: NCT03787602

Public ClinicalTrials.gov record NCT03787602. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve

Study identification

NCT ID: NCT03787602
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Enrollment: 115 participants

Conditions and interventions

Conditions

Merkel Cell Carcinoma

Interventions

KRT-232 Drug
Avelumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 18, 2019
Primary completion: Oct 31, 2024
Completion: Jul 31, 2025
Last update posted: Mar 1, 2023

2019 – 2025

United States locations

U.S. sites: 14
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of Colorado Anschutz Medical Campus	Aurora	Colorado	80045	Recruiting
Miami Cancer Institute	Miami	Florida	33176	Recruiting
Moffitt	Tampa	Florida	33612	Recruiting
Northwestern Memorial Hospital	Chicago	Illinois	60612	Recruiting
Norton Healthcare	Louisville	Kentucky	40202	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215-5418	Recruiting
University of Michigan	Ann Arbor	Michigan	48109	Recruiting
Memorial Sloan-Kettering Cancer Center	New York	New York	10021	Recruiting
Mount Sinai Hospital	New York	New York	10029	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111-2434	Active, not recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting
University of Texas MD Anderson	Houston	Texas	77030	Recruiting
Inova Health Care Services	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03787602, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 1, 2023 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03787602 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →